EICHORCondition: Advanced Solid Tumor · Sponsor: The Affiliated Hospital Of Guizhou Medical University
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is an open-label, prospective, exploratory clinical study, which is divided into two phases: dose escalation phase (Phase Ia) and expansion phase (Phase Ib). After completing the dose-escalation phase (Stage Ia) (5-11 patients), the investigator will select the dose group (RP2D) based on safety, tolerability, and preliminary immune-related characteristics and efficacy data, and choose 2-3 advanced solid tumors to enter the expansion phase (Stage Ib).
This description comes directly from the study's public registry record.
Shengfa Su, MD,PhD · +86-13608550432 · sushengfa2005@163.com
Bing Lu, MD · +86-13809432527 · lbgymaaaa@163.com
Always discuss trial participation with your own doctor first.
| The Affiliated Hospital of Guizhou Medical University | Guiyang, China/Guizhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06497010